IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Dosing Guide
Administration Guidelines
Injection Sites:
- Abdomen (2 inches from navel) - preferred site
- Anterior thigh - good alternative
- Posterior upper arm - with assistance if needed
- Use insulin syringes (29-31 gauge, 0.5-1.0 mL capacity)
Rotation Schedule:
- Rotate between at least 4-6 different sites daily
- Common pattern: Right abdomen → Left abdomen → Right thigh → Left thigh
- Keep a log of injection sites to ensure proper rotation
- Avoid areas with scars, bruises, or previous reactions
Timing:
- Post-workout (within 30 minutes) - optimal for muscle growth
- Morning fasted (minimum 2-hour fast) - for maximum sensitivity
- Split dosing possible for higher doses (morning + post-workout)
- Avoid injecting within 2 hours of bedtime
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.